FEMASYS INC (FEMY) Stock News

NASDAQ:FEMY - US31447E1055 - Common Stock

0.5151 USD

-0.06 (-9.79%)

Last: 8/25/2025, 8:19:01 PM

0.4301 USD

-0.09 (-16.5%)

After Hours: 8/25/2025, 8:19:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

FEMY Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Femasys Inc.

Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform

5 days ago - By: Femasys Inc.

Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform

6 days ago - By: Femasys Inc.

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

6 days ago - By: Femasys Inc.

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

17 days ago - By: The Motley Fool

Femasys Revenue Jumps 85 Percent in Q2

3 months ago - By: Benzinga

The Analyst Verdict: Femasys In The Eyes Of 6 Experts

4 months ago - By: Benzinga

Analyst Expectations For Femasys's Future

17 days ago - By: Zacks Investment Research - Mentions: GRAL

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

17 days ago - By: Femasys Inc.

Femasys Announces Second Quarter Financial Results for 2025

17 days ago - By: Femasys Inc.

Femasys Announces Second Quarter Financial Results for 2025

18 days ago - By: Zacks Investment Research - Mentions: DTIL

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

19 days ago - By: Zacks Investment Research - Mentions: VIR

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

20 days ago - By: Femasys Inc.

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

20 days ago - By: Femasys Inc.

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

2 months ago - By: Femasys Inc.

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

2 months ago - By: Femasys Inc.

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

2 months ago - By: Femasys Inc.

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

2 months ago - By: Femasys Inc.

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

2 months ago - By: Femasys Inc.

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

3 months ago - By: Femasys Inc.

Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

3 months ago - By: Femasys Inc.

Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

3 months ago - By: Femasys Inc.

Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million

3 months ago - By: Femasys Inc.

Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million

3 months ago - By: Femasys Inc.

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

3 months ago - By: Femasys Inc.

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

4 months ago - By: Zacks Investment Research - Mentions: LXRX

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: Femasys Inc.

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

4 months ago - By: Femasys Inc.

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

4 months ago - By: Zacks Investment Research - Mentions: CRIS

Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: BMRN

BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates

5 months ago - By: Zacks Investment Research - Mentions: BMRN

Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates

5 months ago - By: Femasys Inc.

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

5 months ago - By: Femasys Inc.

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update